How to Diagnose Anaphylaxis
Anaphylaxis is diagnosed clinically using the NIAID/FAAN criteria when ANY ONE of three specific clinical patterns is present, without requiring laboratory confirmation. 1
The Three Diagnostic Criteria
Anaphylaxis is highly likely when any one of the following is fulfilled 1:
Criterion 1: Skin/Mucosal Involvement PLUS Respiratory or Cardiovascular Compromise
- Sudden onset (minutes to several hours) of skin or mucosal symptoms (generalized hives, itching, flushing, swollen lips/tongue/uvula)
- AND at least one of:
- Respiratory symptoms: shortness of breath, wheeze, cough, stridor, hypoxemia
- Reduced blood pressure OR end-organ dysfunction (hypotonia/collapse, incontinence)
Criterion 2: Multi-System Involvement After Allergen Exposure
Two or more of the following occurring suddenly after exposure to a likely allergen:
- Skin/mucosal symptoms (generalized hives, itch-flush, swollen lips/tongue/uvula)
- Respiratory symptoms (shortness of breath, wheeze, cough, stridor, hypoxemia)
- Reduced blood pressure or end-organ dysfunction (hypotonia/collapse, incontinence)
- Gastrointestinal symptoms (crampy abdominal pain, vomiting)
Criterion 3: Isolated Hypotension After Known Allergen
Reduced blood pressure after exposure to a known allergen for that patient (minutes to several hours):
- Adults: Systolic BP <90 mm Hg OR >30% decrease from baseline
- Infants (1 month-1 year): Systolic BP <70 mm Hg
- Children (1-10 years): Systolic BP <(70 mm Hg + [2 × age])
- Children (11-17 years): Systolic BP <90 mm Hg 1
Critical Diagnostic Nuances
Clinical Judgment Supersedes Criteria
The diagnostic criteria should not replace clinical judgment. 1 For example, a patient receiving immunotherapy who develops generalized urticaria immediately after injection may warrant epinephrine for impending anaphylaxis even before meeting full diagnostic criteria. However, this remains controversial and requires careful clinical assessment.
Important Distinctions
- Isolated urticaria after allergen exposure may respond to antihistamines and should be distinguished from anaphylaxis requiring epinephrine 1
- Anaphylaxis can occur WITHOUT skin involvement - up to 20% of cases lack cutaneous manifestations 1
- Anaphylaxis can occur WITHOUT hypotension - the criteria specifically allow diagnosis in hemodynamically stable patients 1
Pediatric Considerations
In infants and children 1:
- Respiratory compromise is more likely than hypotension
- Shock manifests initially as tachycardia rather than hypotension
- Normal heart rate: 80-120 beats/minute at age 3 years; 70-115 beats/minute after age 3 years
Validation and Performance
The NIAID/FAAN criteria were prospectively validated in emergency department settings with:
- Positive likelihood ratio: 3.26
- Negative likelihood ratio: 0.07 1
This demonstrates strong diagnostic utility, though the criteria were designed for sensitivity (capturing true cases) rather than specificity.
Laboratory Testing: Adjunctive, Not Diagnostic
Laboratory tests have poor sensitivity and cannot rule out anaphylaxis. 1 Serum tryptase may support the diagnosis when elevated but is not required for diagnosis and is often normal in anaphylaxis.
Retrospective Diagnosis
A patient presenting to the emergency department asymptomatic but with a history meeting NIAID/FAAN criteria should still receive an anaphylaxis diagnosis, even though acute epinephrine is no longer indicated 1. This is critical for proper documentation, patient education, and prevention planning.
Common Diagnostic Pitfalls
- Waiting for hypotension - Many clinicians under-diagnose anaphylaxis in stable patients with multi-system involvement
- Requiring skin findings - Anaphylaxis can present without any cutaneous manifestations, particularly after insect stings 1
- Over-relying on tryptase - Normal tryptase does not exclude anaphylaxis 1
- Confusing epinephrine administration with diagnosis - Epinephrine use should not be used as a surrogate for diagnosing anaphylaxis 2
Updated Criteria Considerations
The 2020 World Allergy Organization criteria identified an additional 6% of patients compared to NIAID/FAAN criteria, primarily those with isolated laryngeal or respiratory involvement 3. The 2024 Anaphylaxis Clinical Support Tool addresses discrepancies between previous criteria 4, though the NIAID/FAAN criteria remain the most widely endorsed and validated framework 1.